Pharma Expansion: Bajaj Healthcare to buy stressed assets from Saraswat Cooperative Bank for Rs 61 crore

The targeted assets have installed capacity of 111 metric tonnes per month and are capable of manufacturing bulk drugs and active pharmaceutical ingredients

Published On 2020-04-30 07:50 GMT   |   Update On 2020-04-30 07:50 GMT

Mumbai: Bajaj Healthcare on Wednesday said it will acquire several stressed assets, including land and factory building, in Maharashtra and Gujarat from Saraswat Cooperative Bank for Rs 61 crore.The company has agreed to acquire stressed assets from Saraswat Cooperative Bank by way of cash consideration of Rs 61 crore subject to closing adjustments, Bajaj Healthcare said in a...

Login or Register to read the full article

Mumbai: Bajaj Healthcare on Wednesday said it will acquire several stressed assets, including land and factory building, in Maharashtra and Gujarat from Saraswat Cooperative Bank for Rs 61 crore.

The company has agreed to acquire stressed assets from Saraswat Cooperative Bank by way of cash consideration of Rs 61 crore subject to closing adjustments, Bajaj Healthcare said in a regulatory filing.

The targeted assets have installed capacity of 111 metric tonnes per month and are capable of manufacturing bulk drugs and active pharmaceutical ingredients (API) like mefenamic acid, artemether, lumefranrine, aceclofenac albendazole, and nimesulide.

The company is buying land and factory building at the Tarapur industrial area in Palghar district of Maharashtra.

Besides, the company will acquire two vacant flats at Jogeshwari (East) in Mumbai.

Further, Bajaj said it will buy vacant industrial land at Dahej in Gujarat.

These APIs are used in pain management, tapeworm infection, and anti-malarial drugs.

"The existing product portfolios of these assets are highly complementary to the current priorities and future focus of the company. This transaction will enable the company to access additional portfolio opportunities going forward," Bajaj Healthcare said.

The company believes that this acquisition will be profitable in long term through a combination of top-line growth, margin accretive, and building newer synergies and consolidation of its presence in the local API market, it added.

The transaction is expected to close by October this year, Bajaj Healthcare said.

Read also: Astellas Pharma acquires Nanna Therapeutics


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News